Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder

por Hussain, S A, Ganesan, R, Hiller, L, Murray, P G, El-Magraby, M M, Young, L, James, N D
Publicado 2003

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial

por Provenzano, E, Vallier, A-L, Champ, R, Walland, K, Bowden, S, Grier, A, Fenwick, N, Abraham, J, Iddawela, M, Caldas, C, Hiller, L, Dunn, J, Earl, H M
Publicado 2013

tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmona...

por Wardley, A M, Hiller, L, Howard, H C, Dunn, J A, Bowman, A, Coleman, R E, Fernando, I N, Ritchie, D M, Earl, H M, Poole, C J
Publicado 2008

NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life

por Earl, H M, Hiller, L, Dunn, J A, Bathers, S, Harvey, P, Stanley, A, Grieve, R J, Agrawal, R K, Fernando, I N, Brunt, A M, McAdam, K, O'Reilly, S, Rea, D W, Spooner, D, Poole, C J
Publicado 2008

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

por Earl, H.M., Hiller, L., Dunn, J., Macpherson, I., Rea, D., Hughes-Davies, L., McAdam, K., Hall, P., Mansi, J., Wheatley, D., Abraham, J.E., Caldas, C., Gasson, S., O'Riordan, E., Wilcox, M., Miles, D., Cameron, D.A., Wardley, A.
Publicado 2021

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial

por Ali, H. R., Dariush, A., Thomas, J., Provenzano, E., Dunn, J., Hiller, L., Vallier, A.-L., Abraham, J., Piper, T., Bartlett, J. M. S., Cameron, D. A., Hayward, L., Brenton, J. D., Pharoah, P. D. P., Irwin, M. J., Walton, N. A., Earl, H. M., Caldas, C.
Publicado 2017

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negativ...

por Earl, H. M., Hiller, L., Dunn, J. A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J. E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L.
Publicado 2017

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised...

por Earl, H M, Hiller, L, Dunn, J A, Vallier, A-L, Bowden, S J, Jordan, S D, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, D A, Agrawal, R, Fernando, I, Brunt, A M, O'Reilly, S M, Crawford, S M, Rea, D W, Simmonds, P, Mansi, J L, Stanley, A, McAdam, K, Foster, L, Leonard, R CF, Twelves, C J, Cameron, D, Bartlett, J MS, Pharoah, P, Provenzano, E, Caldas, C, Poole, C J
Publicado 2012